Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas
Sponsor
Zhejiang University (Other)
Overall Status
Completed
CT.gov ID
NCT05352204
Collaborator
(none)
900
1
23.5
38.4
Study Details
Study Description
Brief Summary
Micronecrosis is a novel pathological feature of hepatocellular carcinoma (HCC). This study was aimed at evaluating the effect of tumor micronecrosis on postoperative transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinomas, and further exploring the value of micronecrosis for guiding TACE in HCC management.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
900 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
The Guiding Value of Tumor Micronecrosis for Using Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas
Actual Study Start Date
:
Apr 30, 2020
Actual Primary Completion Date
:
Jan 1, 2022
Actual Study Completion Date
:
Apr 14, 2022
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| micronecrosis(+) group
|
Procedure: transcatheter arterial chemoembolization
transcatheter arterial chemoembolization after liver resection
|
| micronecrosis(-) group
|
Outcome Measures
Primary Outcome Measures
- overall survival [after liver resection until June 1, 2020]
the number of months from the date of surgery to the date of the last follow-up visit or time of death.
Secondary Outcome Measures
- disease-free survival [after liver resection until June 1, 2020]
the number of months from the date of surgery to the date of first confirmable recurrence or death
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- (1) pathologically confirmed HCC (2) achievement of R0 resection.
Exclusion Criteria:
- (1) simultaneous presence of other tumors ; (2) receipt of preoperative anti-tumoral treatments; (3) concurrent treatment with other antitumoral therapies in combination with TACE; (4) tumor necrosis that could be observed by gross examination; (5) a lack of necessary preoperative laboratory test results.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | the First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou | Zhejiang | China | 310009 |
Sponsors and Collaborators
- Zhejiang University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
TingBo Liang,
FACS,
Zhejiang University
ClinicalTrials.gov Identifier:
NCT05352204
Other Study ID Numbers:
- PTHCC
First Posted:
Apr 28, 2022
Last Update Posted:
Apr 28, 2022
Last Verified:
Apr 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by TingBo Liang,
FACS,
Zhejiang University
Additional relevant MeSH terms: